Privately held DreaMed Diabetes, Ltd. said the U.S Food and Drug Administration approved for marketing its artificial intelligence-based software Advisor Pro for the management of diabetes.

The Israeli company said the cloud-based digital solution is used to assist healthcare providers in the management of people with type 1 diabetes who use insulin pumps and continuous glucose monitoring.

The software generates insulin delivery recommendations by analyzing information from glucose monitoring systems and insulin pumps.

DreaMed said Advisor Pro received the EU's CE mark designation for assisting healthcare professionals in the management of type 1 diabetes.